BioInvent buys Merck single-use tech to up mAb capacity

By Gareth Macdonald contact

- Last updated on GMT

BioInvent facility in Lund, Sweden
BioInvent facility in Lund, Sweden

Related tags: Biotechnology

BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.

The deal – financial terms of which were not provided – will see BioInvent install 3-, 50-, 200- and 1000-liter bioreactors from Merck’s Mobius range at the plant, with the idea being the range of sizes will simplify production scale-up.

Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent, said: “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system​.”

BioInvent outlined its plan to increased mAb production capacity last September, citing the expansion of a customer contract as the driver.

At the time, the firm told us it used 500L Wave systems provided by GE Healthcare, but intended to install a 1,000L Single Use bioreactor (SUB).

Related topics: Upstream Processing, Bioreactors

Related news

Related products

show more

Manufacturing of hiPSC-Derived Cardiomyocytes

Manufacturing of hiPSC-Derived Cardiomyocytes

Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020 | Application Note

Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us

Products

View more

Webinars